CLOT Conversations

Thrombosis Canada
  • 5.0 (1)
  • MEDICINE
  • UPDATED BIWEEKLY

Unlock the latest breakthroughs in thrombosis diagnosis and management with CLOT Conversations - the must-listen podcast for healthcare professionals. Join hosts Dr Jameel Abdulrehman, a Hematologist with specialization in Thrombosis and Hemostasis at the University Health Network in Toronto, and David Airdrie, the Executive Director of Thrombosis Canada, as they delve into new research and explore the evolving field of thrombosis in 15 to 30 minute easily digestible episodes. Learn from the experts and stay ahead of the curve with Thrombosis Canada, the organization dedicated to promoting excellent patient care and improved outcomes for patients with thrombosis. Access our vast resources, tools, and programs at https://thrombosiscanada.ca and stay informed with CLOT Conversations - your go-to source for all things thrombosis.

  1. 2D AGO

    ARTESiA: Apixaban vs Aspirin Bleeding Risk with Dr D Siegal

    Send a text Major bleeding remains the principal complication of oral anticoagulation. In patients with device-detected subclinical atrial fibrillation, the decision to anticoagulate requires careful balancing of stroke prevention against bleeding risk. In this episode of CLOT Conversations, Dr. Deborah Siegal discusses a prespecified subanalysis of the ARTESiA randomized clinical trial, recently published in JAMA Cardiology. ARTESiA demonstrated a 37% reduction in stroke and systemic embolism with apixaban compared to aspirin — but at the cost of increased major bleeding. This subanalysis goes deeper, examining the site, severity, and clinical course of bleeding events. Most bleeding was gastrointestinal and non-critical. Rates of intracranial and fatal bleeding were low and similar between treatment arms. The majority of events were not clinical emergencies, and many were defined by hemoglobin decline rather than catastrophic presentation. We explore what these findings mean for individualized risk assessment, the importance of modifiable bleeding risk factors such as NSAID use, and how physicians and patients can approach shared decision-making in subclinical AF. Abstract (subscription required for full paper):  Siegal DM, Sticherling C, Healey JS, McIntyre WF, Christensen LS, Parkash R, Vanassche T, Conen D, Gold M, Granger CB, Nielsen JC. Major Bleeding With Apixaban vs Aspirin: A Subanalysis of the ARTESiA Randomized Clinical Trial. JAMA cardiology. 2025 Dec;10(12):1305-14. https://jamanetwork.com/journals/jamacardiology/fullarticle/2841075 Support the show https://thrombosiscanada.ca Take a look at our healthcare professional and patient resources, videos and publications on thrombosis from the expert members of Thrombosis Canada

    18 min

  2. 12/16/2025

    WAVe Study: Cancer, Obesity, Anticoagulation with Dr Tzu-Fei Wang and Dr Gregoire Le Gal

    Send us a text Obesity presents a persistent challenge in the management of cancer-associated thrombosis, particularly when prescribing low molecular weight heparin beyond standard dose caps. In this episode of CLOT Conversations, host Dr. Jameel Abdulrehman is joined by Dr. Tzu-Fei Wang and Dr. Grégoire Le Gal to discuss findings from the WAVe study, a multicenter prospective cohort study evaluating weight-adjusted dalteparin dosing in patients over 90 kg with acute cancer-associated venous thromboembolism. The conversation examines bleeding and thrombotic outcomes, mortality, and trough anti-Xa levels, including insights into bioaccumulation and twice-daily versus once-daily dosing. The guests also address study limitations, dose capping in patients with very high body weight, and how WAVe fits into current practice amid increasing DOAC use. This episode provides practical, evidence-informed guidance for clinicians navigating anticoagulation decisions in obese patients with cancer. To access the full publication:  https://onlinelibrary.wiley.com/doi/full/10.1002/ajh.70127  Please consider supporting Thrombosis Canada by donating today or consider a monthly donation starting at $10: ThrombosisCanada.ca/donate Support the show https://thrombosiscanada.ca Take a look at our healthcare professional and patient resources, videos and publications on thrombosis from the expert members of Thrombosis Canada

    22 min

  3. 12/03/2025

    ROXI-VTE Trials Explained: Dr. Jeff Weitz on Next-Generation Thrombosis Prevention

    Send us a text In this episode of CLOT Conversations, co-hosts Dr. Jamil Abdul-Rahman and Dr. Maha Othman have an in-depth discussion with leading thrombosis expert Dr. Jeff Weitz. Together, they unpack new findings from The Lancet on RGN-9933 and RGN-7508, two investigational factor XI inhibitors evaluated in the ROXI-VTE I and II phase-2 trials. These studies examine how targeted inhibition of factor XI may reduce post-operative venous thromboembolism with potentially lower bleeding risk than current anticoagulants. Dr. Weitz explains the distinct mechanisms of the two antibodies, the role of factor XII-mediated activation in post-operative VTE, key efficacy and safety outcomes, and how these early-phase studies set the stage for ongoing phase-2 and phase-3 trials—including ROXI-CATH, ROXI-Aspirin, and emerging AF and stroke-prevention research. This episode is essential listening for clinicians interested in the rapidly evolving landscape of anticoagulation and next-generation therapies that may offer safer options for patients undergoing orthopedic surgery and beyond. Read the full Lancet publication by clicking on the link below and explore more thrombosis resources at thrombosiscanada.ca. Become a Thrombosis Champion, be a monthly donor at https://thrombosiscanada.ca/donate https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)02097-5/abstract [Note: full access requires a subscription] Support the show https://thrombosiscanada.ca Take a look at our healthcare professional and patient resources, videos and publications on thrombosis from the expert members of Thrombosis Canada

    22 min
  4. Diagnosing the “Second Clot”: Lessons from PREDICTORS with Dr Vicky Mai and Dr Grégoire Le Gal

    10/03/2025

    Diagnosing the “Second Clot”: Lessons from PREDICTORS with Dr Vicky Mai and Dr Grégoire Le Gal

    Send us a text Diagnosing recurrent venous thromboembolism (VTE) remains one of the biggest clinical challenges in thrombosis medicine. In this episode, Dr. Vicky Mai and Dr. Grégoire Le Gal join us to discuss the international PREDICTORS study (JTH, 2025), which evaluated the performance of commonly used clinical decision rules (Wells and Geneva scores) in patients with suspected recurrent VTE. They share why symptoms can be misleading, how residual clots complicate imaging, and what their findings mean for the safe use of D-dimer and anticoagulation status in clinical practice. Reference: Mai, V., Martens, E. S., Righini, M., Schulman, S., Thiruganasambandamoorthy, V., Kahn, S. R., ... & Le Gal, G. (2025). Performance of clinical decision rules in patients presenting with suspected recurrent venous thromboembolism: a multicenter prospective cohort study. Journal of Thrombosis and Haemostasis. https://www.sciencedirect.com/science/article/abs/pii/S1538783625004088 Support the show https://thrombosiscanada.ca Take a look at our healthcare professional and patient resources, videos and publications on thrombosis from the expert members of Thrombosis Canada

    17 min

  5. 09/05/2025

    Low Health Literacy in Pediatric Thrombosis: Clinical Risks and Realities - L. Avila and J. Vincelli

    Send a text This episode reviews findings from a cross-sectional study at SickKids on health literacy in pediatric VTE patients and caregivers (Res Pract Thromb Haemost, 2025). Among 101 participants, 74% of adolescents and 59% of parents/caregivers demonstrated low general health literacy using REALM, HAS-A, and eHEALS instruments. Communication with providers was the most affected domain, and fewer than half of participants were satisfied with their thrombosis knowledge. Adolescents frequently overestimated their understanding, underscoring the need for simplified educational resources and a “universal precautions” approach to health literacy in pediatric thrombosis care. AboutKidsHealth Thrombosis Hub: https://www.aboutkidshealth.ca/thrombosis Bastas, D., Mancini, A., Wong, G., Brandão, L. R., Mukaj, S., Vincelli, J., ... & Avila, L. (2025). Health literacy in pediatric thrombosis: a landscape analysis. Research and Practice in Thrombosis and Haemostasis, 9(1), 102653. Publication Link: https://www.rpthjournal.org/article/S2475-0379%2824%2900348-0/fulltext Support the show https://thrombosiscanada.ca Take a look at our healthcare professional and patient resources, videos and publications on thrombosis from the expert members of Thrombosis Canada

    16 min

  6. 08/28/2025

    Children and PE: Outcomes You Need to Know - L. Avila and J. Vincelli

    Send a text In this episode, Dr. Laura Avila and Jennifer Vincelli discuss their Blood publication on long-term outcomes of pediatric pulmonary embolism. Among 150 patients, ~30% had incomplete PE resolution and 9% experienced recurrence, but persistent sequelae were rare. True post-PE syndrome occurred in 9%, with only one case of CTEPH. The findings highlight the value of structured follow-up, attention to underlying conditions, and promoting physical activity to counter deconditioning. To access the publication use this URL: https://thrombosiscan.info/CLOT-CONVO-46 Support the show https://thrombosiscanada.ca Take a look at our healthcare professional and patient resources, videos and publications on thrombosis from the expert members of Thrombosis Canada

    15 min

  7. 08/08/2025

    Navigating Thromboprophylaxis in Orthopedic Surgery

    Send us a text In this episode of CLOT Conversations, we discuss the newly developed Orthopedic Surgery VTE Thromboprophylaxis Guideline Summary. Dr. Marc Carrier, a hematologist and key author, highlights the need for a multidisciplinary approach in managing venous thromboembolism (VTE) risks, particularly in orthopedic surgery. The conversation covers preoperative risk assessments, options for pharmacological and mechanical thromboprophylaxis, and the evolving landscape of surgical techniques that influence thrombosis risk. The episode emphasizes the importance of providing clinicians with practical tools to effectively navigate VTE prevention. Access the full review paper here: https://thrombosiscanada.ca/uploads/publications/WhitePapers/TC135_VTE_Whitepaper_v4.pdf Support the show https://thrombosiscanada.ca Take a look at our healthcare professional and patient resources, videos and publications on thrombosis from the expert members of Thrombosis Canada

    12 min

  8. 08/01/2025

    Risk Factors for Recurrent VTE in Cancer with Dr Faizan Khan

    Send us a text In this episode of CLOT Conversations, experts discuss recent research on cancer-associated thrombosis and the predictors of recurrent venous thromboembolism (VTE) and anticoagulant-related bleeding. Dr. Faizan Khan, a leading researcher in the field, explains the results of their study that aimed to offer a comprehensive understanding of the prognostic factors associated with these risks. Hear what he says about the evidence for associations of several patient- and cancer-related factors, and the risk of recurrent VTE. This research is expected to inform clinical practice by promoting a more individualized approach to anticoagulant management in cancer patients. Reference:  Khan, F., Tritschler, T., Marx, C. E., Lanting, V., Rochwerg, B., Tran, A., ... & Carrier, M. (2025). Predictors of recurrent venous thromboembolism and bleeding in patients with cancer: a meta-analysis. European Heart Journal, ehaf453. https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehaf453/8170116?login=false Support the show https://thrombosiscanada.ca Take a look at our healthcare professional and patient resources, videos and publications on thrombosis from the expert members of Thrombosis Canada

    20 min
See All (52)

About

Unlock the latest breakthroughs in thrombosis diagnosis and management with CLOT Conversations - the must-listen podcast for healthcare professionals. Join hosts Dr Jameel Abdulrehman, a Hematologist with specialization in Thrombosis and Hemostasis at the University Health Network in Toronto, and David Airdrie, the Executive Director of Thrombosis Canada, as they delve into new research and explore the evolving field of thrombosis in 15 to 30 minute easily digestible episodes. Learn from the experts and stay ahead of the curve with Thrombosis Canada, the organization dedicated to promoting excellent patient care and improved outcomes for patients with thrombosis. Access our vast resources, tools, and programs at https://thrombosiscanada.ca and stay informed with CLOT Conversations - your go-to source for all things thrombosis.

Information

  • Creator
    Thrombosis Canada
  • Years Active
    2022 - 2026
  • Episodes
    52
  • Rating
    Clean
  • Copyright
    © 2026 CLOT Conversations
  • Show Website
    CLOT Conversations